ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis
15 mars 2024 03h05 HE
|
ResMed Inc.
ResMed announced the results of its 2024 Global Sleep Survey, uncovering a world in sleep crisis and encouraging people to discover their sleep superpowers
Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask
06 mars 2024 09h05 HE
|
ResMed Inc.
ResMed unveils the AirFit F40, an ultra-compact full-face CPAP mask offering the comfort of smaller masks without sacrificing performance.
ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea
12 févr. 2024 16h16 HE
|
ResMed Inc.
ResMed launched AirCurve 11 bilevel devices to enhance sleep apnea device therapy options.
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024
24 janv. 2024 16h05 HE
|
ResMed Inc.
Year-over-year revenue grows 12%, operating profit down 2%, non-GAAP operating profit up 20%Resumed share repurchase program, repurchased $50 million during quarter Note: A webcast of ResMed’s...
ResMed to Report Second Quarter Fiscal 2024 Earnings on January 24, 2024
03 janv. 2024 16h05 HE
|
ResMed Inc.
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2024 on...
ResMed Announces Participation in the 42nd Annual J.P. Morgan Healthcare Conference
27 déc. 2023 16h05 HE
|
ResMed Inc.
SAN DIEGO, Dec. 27, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer and chair of the board, will present at the 42nd Annual J.P. Morgan...
ResMed Notifies Customers About Updated Instructions and Labeling for Masks with Magnets Due to Potential Interference with Certain Medical Devices
20 déc. 2023 16h05 HE
|
ResMed Inc.
SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) is conducting a voluntary global field action to update its guides for all masks with magnets to inform users about...
ResMed Secures Significant Victory in Patent Fight Against New York University
11 déc. 2023 16h05 HE
|
ResMed Inc.
ResMed Secures Significant Victory in Patent Fight Against New York University
Study Estimates a 23% Increase in COPD by 2050, Representing 600 Million Patients Globally
07 déc. 2023 15h34 HE
|
ResMed Inc.
New study shows Chronic Obstructive Pulmonary Disease (COPD) increasing globally through 2050, with 47% growth among women.
ResMed Adopts New Operating Model to Accelerate Long-term Growth
09 nov. 2023 16h05 HE
|
ResMed Inc.
Justin Leong appointed Chief Product Officer, effective immediately.Katrin Pucknat appointed Chief Marketing Officer, effective immediately.Mike Fliss appointed Chief Revenue Officer, effective...